Vaccinex Inc (VCNX)

개요 뉴스 가격 이력 Financials VCNX 왜 하락? 토론 예측 주식 분할

Vaccinex Inc 주식(VCNX)의 최신 뉴스

Vaccinex Inc (VCNX)

Vaccinex Inc 주식(VCNX)의 최신 뉴스

Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India

Vaccinex presents promising cancer treatment data at ASCO - Investing.com

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting | VCNX Stock News - GuruFocus

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewswire

Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan

Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire

Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World

Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa

Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times

Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq

Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire

VACCINEX, INC. SEC 10-K Report - TradingView

Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews

Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail

Vaccinex Delays Yearly Report Filing - TipRanks

Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa

Vaccinex director resigns, no disagreement cited - Investing.com India

Stocks in play: Neo Performance Materials Inc. - The Globe and Mail

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire

Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan

Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World

Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News

RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next? - Defense World

Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR

Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com

Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World

Vaccinex to be delisted from Nasdaq over equity shortfall By Investing.com - Investing.com South Africa

United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India

Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com India

Vaccinex Shares Tumble 63% On Nasdaq Delisting - MarketWatch

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance

Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com

Vaccinex receives delisting notice from Nasdaq, shares down over 49% - MSN

Vaccinex Announces Receipt of Delisting Notification from Nasdaq - The Manila Times

VCNX과 유사한 종목